Related Experiment Video
Updated: Dec 1, 2025
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
Shiga Toxin-Producing Escherichia coli Transmission via Fecal Microbiota Transplant
Caroline Zellmer1, Mohamad R A Sater2, Miriam H Huntley2
1OpenBiome, Cambridge, Massachusetts, USA.
Abstract:
Fecal microbiota transplantation (FMT) is recommended therapy for multiply recurrent Clostridioides difficile infection. We report adverse events in 7 patients who received FMT from a stool donor who was colonized with Shiga toxin-producing Escherichia coli (STEC). No patients died of FMT-transmitted STEC. Improved screening can likely avoid future transmission.
Insights
Fecal microbiota transplantation (FMT) can transmit Shiga toxin-producing Escherichia coli (STEC). While no patients died from STEC in this study, improved donor screening is crucial to prevent future transmissions during FMT procedures.
Area of Science:
- Microbiology
- Infectious Diseases
- Gastroenterology
Background:
- Fecal microbiota transplantation (FMT) is a recommended therapy for multiply recurrent Clostridioides difficile infection.
- The safety of FMT relies heavily on donor screening to prevent pathogen transmission.
Purpose of the Study:
- To report adverse events in patients receiving FMT from a donor colonized with Shiga toxin-producing Escherichia coli (STEC).
- To highlight the importance of enhanced screening protocols in FMT.
Main Methods:
- Retrospective case review of 7 patients who received FMT from a single stool donor.
- Microbiological analysis of donor stool and patient outcomes.
Main Results:
- All 7 patients received FMT from a donor colonized with STEC.
- No patients died from FMT-transmitted STEC.
- Clinical outcomes related to STEC transmission were monitored.
Conclusions:
- FMT carries a risk of transmitting STEC from colonized donors.
- Improved and rigorous donor screening is essential to mitigate the risk of STEC transmission via FMT.
- Enhanced screening protocols can prevent future adverse events associated with FMT.
